Renoprotective Effects of Soluble Guanylate Cyclase (sGC) Activation vs. ACE Inhibition in a CKD Model with Volume/Salt-Dependent Hypertension
Rattachement africain : us, de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: BP control using renin-angiotensin system (RAS) blockade is the current standard of care for CKD. However, outcomes remain suboptimal in part because adequate BP reductions are difficult to achieve in the volume expanded CKD states with RAS blockade even with additional antihypertensives. Given that endothelial dysfunction and/or NO loss accelerate the progression of both diabetic and non-diabetic CKD, sGC activators represent potential novel therapeutic interventions in CKD. Methods: Two weeks after 3/4 nephrectomy and instrumentation for chronic BP radiotelemetry, male Sprague-Dawley rats were switched to a 4% NaCl diet after proteinuria measurements. After 2 weeks on the 4% NaCl diet and repeat proteinuria measurements, the rats started receiving vehicle only (5 ml/kg), the ACE inhibitor, enalapril (50 mg/kg), the sGC activator (BR-11257) (10 mg/kg), or the combination of BR11257 + enalapril by daily gavage. After 6 weeks of therapy and final proteinuria measurements, the rats were sacrificed for a blinded histologic assessment of % glomerulosclerosis (GS). Results: In this CKD model with volume (salt) dependent hypertension (HTN), BR-11257 alone or in combination with enalapril but not enalapril alone, significantly lowered BP, ameliorated proteinuria and reduced the development of GS (Table). Linear regression analysis showed a strong correlation between individual systolic BP (SBP) and % GS (r=0.69, n=63, p < 0.0001), without a significant difference in the slope of the relationship (0.3 ± 0.04) between treatment groups. Conclusions: These data strongly support the therapeutic potential of sGC activators alone or in combination with RAS blockade in hypertensive and proteinuric CKD states. Funding: Commercial Support - Bayer AG
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Renoprotective Effects of Soluble Guanylate Cyclase (sGC) Activation vs. ACE Inhibition in a CKD Model with Volume/Salt-Dependent Hypertension
- Date Crossref
- 01/10/2021
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.